Eli Lilly & CO Form 4 insider transactions

Anne E. White, EVP & President of Lilly Neuroscience, reported the acquisition of 4,124 shares of Eli Lilly common stock through restricted stock units and the disposition of 1,844 shares to cover tax obligations.

Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co., sold a portion of its holdings in multiple transactions on January 31, 2024.

Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co., sold a portion of its holdings in multiple transactions on January 30, 2024.

Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co., sold 54,032 shares of common stock at an average price of $645.07 per share on January 29, 2024.

Gabrielle Sulzberger, a director at Eli Lilly, acquired 16 shares of common stock through a deferral plan.

Director Juan R. Luciano acquired 23 shares of Eli Lilly common stock through a deferral plan, to be settled after separation from service.

Eli Lilly director Kimberly H. Johnson acquired 15 shares of common stock through a deferral plan, as reported in a recent SEC filing.

Mary Lynne Hedley, a director at Eli Lilly, acquired 16 shares of common stock through a deferral plan, while also holding 1,437 shares directly and 98 shares indirectly through a trust.

Ralph Alvarez, a director at Eli Lilly, acquired 19 shares of common stock through a deferral plan on January 16, 2024.

Lilly Endowment Inc. sold 1,180 shares of Eli Lilly & Co. common stock in multiple transactions on January 16, 2024.

Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co., sold a portion of its holdings in multiple transactions on January 11, 2024.

Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co., sold a portion of its common stock holdings in multiple transactions on January 10, 2024.

Lilly Endowment Inc. sold a total of 34,538 shares of Eli Lilly & Co. common stock in multiple transactions on January 9, 2024, at weighted average prices ranging from $630.389 to $633.41.

Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co., sold a portion of its holdings in multiple transactions on January 4, 2024.

Gabrielle Sulzberger, a director at Eli Lilly, acquired 9 shares of common stock through a deferral plan.

Director Juan R. Luciano acquired 25 shares of Eli Lilly common stock through a deferral plan, with settlement occurring after separation from service.

Eli Lilly director Kimberly H. Johnson acquired 17 shares of common stock through a deferral plan, as reported in a recent SEC filing.

Mary Lynne Hedley, a director at Eli Lilly, acquired 17 shares of common stock through a deferral plan, while also holding 98 shares indirectly through a trust.

Director J. Erik Fyrwald acquired 17 shares of Eli Lilly stock at $579.76 per share through a deferral plan.

Director Ralph Alvarez acquired 20 shares of Eli Lilly common stock through a deferral plan, with settlement occurring after separation from service.